A First in the Middle East and North Africa
KFSHRC Launches Mobile Stroke Unit to Accelerate Patient Treatment
Neuro
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.
Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical
SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
Remedy Pharmaceuticals’ Phase 3 Trial in Large Lesion Stroke Patients Demonstrates Statistically Significant Effect at One Year
NEW YORK, Oct. 1, 2024 /PRNewswire/ — Remedy Pharmaceuticals today announced additional promising data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in patients with Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke, characterized by…
Synchron Announces Positive Results from U.S. COMMAND Study of Endovascular Brain-Computer Interface
NEW YORK–(BUSINESS WIRE)–Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period. “The COMMAND study results represent a major medical milestone, confirming the safety of the Stentrode […]
CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery Method
Gene therapy delivered via CereVasc’s endovascular delivery approach reached key targets in the central nervous system after injection into the cerebellopontine angle resulting in broad biodistribution The eShunt approach has the potential to provide doctors and biopharma partners with a…
Toro Neurovascular Announces First Patient Treated in Clinical Trial for SuperBore Aspiration Catheter for Acute Ischemic Stroke
September 24, 2024 10:00 AM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Toro Neurovascular, an innovative medical device company, is excited to announce the successful treatment of the first patient using its Toro 88 SuperBore Aspiration Catheter as part of a first-in-man clinical study. The procedure, performed by esteemed neurosurgeon Nobuyuki Sakai, […]
Fzata, Inc. Announces Multi-million Dollar NIH Grant
HALETHORPE, Md., Sept. 24, 2024 /PRNewswire/ — Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants…
Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and…
Recent
Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Nicklaus Children’s Hospital’s Heart Institute Performs Florida’s First Partial Heart Transplant
Popular
- No commented posts yet